LIVE CONFERENCE: Available until 5/31/24
ENDURING CONFERENCE: Available until 7/31/24
If you did not claim CE before the expiration date, you will need to reach out to the CE provider directly at https://paceducation.com/.
1. Create an account and fill out your profile using the same email address that you used to register for the conference. (Note: to create an account you will click the “Sign up now” button)
2. Select the number of credits you earned during the live conference. To calculate your credits, click here.
3. Click “Save and continue to Evaluation”
4. Once you have filled out the evaluation form, click “Submit Evaluation”
5. If you need to claim pharmacology credit, you will be able to click on the “Claim ANCC-APRN Certificate button. Screenshot is below
2024 Contraceptive Technology Virtual Conference
- April 25, 2024
- Jointly provided by Partners for Advancing Clinical Education (PACE) and American Sexual Health Association
- Enduring activity available May 6, 2024 – June 31, 2024
Target Audience
This activity is intended for physicians, registered nurses, physician’s associate, physician assistant, nurse practitioner, other APRN.
Educational Objectives
Upon completion of this activity, participants should be able to:
| OBJECTIVE 1 |
| Explain how to address contraception needs and preferences for clients with chronic medical conditions; lupus, obesity, bleeding disorders, and cardiac conditions. |
| OBJECTIVE 2 |
| Using patient centered language, describe 2 management options for clients who experience unacceptable bleeding. |
| OBJECTIVE 3 |
| Demonstrate inclusive, sensitive care with individuals identifying as a sexual or gender minority. |
| OBJECTIVE 4 |
| List 3 health advantages for individuals using fertility-awareness based methods correctly. |
| OBJECTIVE 5 |
| Discuss evidence-based treatments for gonorrhea, trichomonas, chlamydia, and syphilis. |
Disclosure of Conflicts of Interest
PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to PACE policies. Others involved in the planning of this activity have no relevant financial relationships.
| Name | Role | Conflicts of INterest |
|---|---|---|
| Anne Burke, MD Johns Hopkins University School of Medicine & Bloomberg School of Public Health | Faculty | Merck – Researcher |
| Patty Cason, NP Envision SRH, UCLA School of Nursing | Faculty and planner | Merck – speaker on non-branded topic Sebela Women’s Health – Consultant Organon – Speaker/ Trainer |
| Carrie Cwiak, MD Emory University School of Medicine | Faculty | Sebela Women’s Health -researcher Springer -Textbook on contraception royalties, patent beneficiary |
| MIles Harris, NP UC Davis Health | Faculty | Has no relevant financial relationships with ineligible companies to disclose |
| Debbie Kowal Contraceptive Technology Communications, Inc. | Faculty | Has no relevant financial relationships with ineligible companies to disclose |
| Chance Krempasky, FNP-BC WHNP-BC AAHIVS Callen-Lorde Community Health Center | Faculty | Has no relevant financial relationships with ineligible companies to disclose |
| Jeanne Marrazzo, MD, MPH, FACP, FIDSA Internal Medicine, Infectious Diseases | Faculty | GSK – Other |
| Anita Nelson, MD David Geffen School of Medicine at UCLA | Faculty | Viatris Pharmaceuticals Inc- Researcher Sumitomo Pharma America, Inc – Researcher Organon & Co, Co Ltd – Researcher Sebela Women’s Health – Researcher Bayer – Advisor, Speaker and Consultant Mayne Pharmaceutical –Advisor, Speaker and Consultant Merck – Researcher Organon & Co – Consultant, Advisor, Speaker Exeltis USA, Inc – Consultant, Advisor, Speaker Sumitomo Pharma America – Consultant, Advisor, Speaker |
| Lola Pellegrino, NP Callen-Lorde Community Health Center | Faculty | Has no relevant financial relationships with ineligible companies to disclose |
| Rachel Peragallo Urrutia, MD, MS University of North Carolina Chapel Hill | Faculty | Has no relevant financial relationships with ineligible companies to disclose |
| Michael Policar, MD University of California San Francisco School of Medicine | Faculty | Has no relevant financial relationships with ineligible companies to disclose |
| Chelsea Polis, PhD Center for Biomedical Research, Population Council | Faculty | Has no relevant financial relationships with ineligible companies to disclose |
| Joely Pritzker, NP Vista Community clinic and Envision SRH | Faculty | Organon – Consultant, Advisor, Speaker |
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and the American Sexual Health Association(ASHA). PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Education
PACE designates this live activity for a maximum of 7.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 7.25 contact hours.
Designated for 3 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as aguideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.